Eli Lilly Stock Plunges Despite Strong Q2 Results Due to Orforglipron Concerns

BTCC / BTCC Square / Global Cryptocurrency /

Author:

Release Time:

2025-08-07 20:42:02

BTCCSquare news:

Eli Lilly's shares tumbled 14.8% despite reporting better-than-expected Q2 2025 earnings, driven by strong sales of Mounjaro and Zepbound. The decline followed mixed results from a Phase 3 trial of oral GLP-1 agonist orforglipron, which showed 12.4% average weight loss but fell short of some Wall Street expectations.

Investors reacted sharply to the 10.3% discontinuation rate in the high-dose group, overshadowing CEO Dave Ricks' Optimism about the drug's commercial potential. The market's punitive response highlights the intense scrutiny facing weight-loss therapies in competitive development pipelines.

By:

Log in to Reply

Chainlink Launches LINK Reserve Initiative to Strengthen Network Sustainability

Articles on this site are sourced from public networks or curated by AI for informational purposes only and do not represent BTCC’s views. Original rights belong to the respective authors. For copyright concerns, please contact [email protected]. BTCC assumes no liability for the accuracy, timeliness, or completeness of this information, and disclaims all liability arising from reliance on such content. This content is for reference only and should not be taken as investment, legal, or commercial advice.